BioIntelliSense BioSticker is FDA-approved

A new on-body sensor sticker will allow 30 days of continuous monitoring of vital signs, sleep status, activity levels—and even body position—for home settings, including dialysis. Fresenius has invested in this technology that aims to allow clinicians to be proactive by health problems or falls sooner, which may reduce the need for ER visits and hospital stays.

Read the full article » | Posted 02-19-2020

Related Articles